Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-811X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma ; volume:17 ; number:1 ; day:28 ; month:10 ; year:2019 ; pages:1-11 ; date:12.2019
Cell communication and signaling ; 17, Heft 1 (28.10.2019), 1-11, 12.2019
- Urheber
-
Ito, Masaoki
Codony-Servat, Carles
Codony-Servat, Jordi
Lligé, David
Chaib, Imane
Sun, Xiaoyan
Miao, Jing
Sun, Rongwei
Cai, Xueting
Verlicchi, Alberto
Okada, Morihito
Molina-Vila, Miguel Angel
Karachaliou, Niki
Cao, Peng
Rosell, Rafael
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-019-0446-z
- URN
-
urn:nbn:de:101:1-2020022622170940176099
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ito, Masaoki
- Codony-Servat, Carles
- Codony-Servat, Jordi
- Lligé, David
- Chaib, Imane
- Sun, Xiaoyan
- Miao, Jing
- Sun, Rongwei
- Cai, Xueting
- Verlicchi, Alberto
- Okada, Morihito
- Molina-Vila, Miguel Angel
- Karachaliou, Niki
- Cao, Peng
- Rosell, Rafael
- SpringerLink (Online service)
Ähnliche Objekte (12)
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Target Mutant KRAS with Molecular Glue
Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Target Mutant KRAS with Molecular Glue
Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Target Mutant KRAS with Molecular Glue
Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers